Health Canada and TGA Update Safety Labels for GLP-1 Medications

Health Canada updated product monographs for Ozempic and Mounjaro on June 23, 2026, forcing a shift in how clinicians manage potential ocular side effects. One month later, Australia’s Therapeutic Goods Administration followed suit, broadening the scope to include Wegovy, Saxenda, and Trulicity. These directives represent a global push to standardize clinical responses to a condition that has become the focus of extensive litigation in the United States.

Jason Goldstein, Senior Litigation Counsel at Parker Waichman LLP, noted that these international mandates move beyond vague warnings by providing concrete protocols for medical intervention. As plaintiffs' counsel in the federal multidistrict litigation pending in the Eastern District of Pennsylvania, the firm argues that manufacturers failed to adequately disclose these risks to the public. While regulators now require urgent ophthalmologic referrals for patients reporting vision changes, the legal battle over whether these warnings came too late for many patients continues to unfold in American courts.